for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

571.92USD

Change

-4.71(-0.82%)

Volume

343,700

Today's Range

567.02

 - 

581.68

52 Week Range

294.86

 - 

664.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
576.63
Open
577.53
Volume
343,700
3M AVG Volume
18.66
Today's High
581.68
Today's Low
567.02
52 Week High
664.64
52 Week Low
294.86
Shares Out (MIL)
106.39
Market Cap (MIL)
61,349.05
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Regeneron Pharmaceuticals Inc Earnings Release

Latest Developments

More

Sanofi Says Dupixent Reduces Severe Asthma Attacks in Children

Regeneron Says Dupixent (Dupilumab) Significantly Reduced Severe Asthma Attacks In Children

Sanofi: Libtayo Monotherapy Increases Overall Survival In First-Line Advanced Non-Small Cell Lung Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board, Director

Leonard S. Schleifer

President, Chief Executive Officer, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

2.11 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

5.9K

2018

6.7K

2019

7.9K

2020(E)

8.2K
EPS (USD)

2017

16.320

2018

22.840

2019

24.670

2020(E)

28.546
Price To Earnings (TTM)
22.32
Price To Sales (TTM)
7.67
Price To Book (MRQ)
6.75
Price To Cash Flow (TTM)
19.14
Total Debt To Equity (MRQ)
24.47
LT Debt To Equity (MRQ)
7.90
Return on Investment (TTM)
26.89
Return on Equity (TTM)
21.62

Latest News

Latest News

Regeneron's drug becomes first FDA-approved Ebola virus treatment

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed for COVID-19.

Top U.S. health official Fauci says Trump no longer coronavirus contagious: CBS interview

U.S. President Donald Trump is no longer capable of spreading the novel coronavirus and can attend a town hall on Thursday without putting others at risk, top U.S. public health official Anthony Fauci said in an interview with CBS Evening News.

U.S. FDA approves Regeneron's drug as first treatment for Ebola virus

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' Inmazeb as the first FDA-approved treatment for the Ebola virus infection in adults and children.

U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 'cure' over safety concern

(This Oct. 13 story corrects the headline and paragraphs 1 and 9 to show the federal government, not Eli Lilly, made the decision to pause a clinical trial of the company’s antibody drug)

U.S. expects over 1 million COVID-19 antibody doses from Regeneron, Lilly in 2020

The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.

Trump says he is pushing to get Regeneron's COVID-19 treatment approved quickly

U.S. President Donald Trump said on Friday he is working to get coronavirus antibody drugs developed by Regeneron Pharmaceuticals Inc and Eli Lilly and Co approved quickly and out to hospitals after his own positive coronavirus treatment experience.

HHS expects over 1 mln antibody doses from Regeneron, Lilly in 2020

A top U.S. health official said on Friday that the government expects to have access to over 1 million doses of Regeneron Pharmaceutical Inc's and Eli Lilly's & Co's antibody treatments for COVID-19 in 2020.

Fauci says 'reasonably good chance' Regeneron antibody therapy helped Trump

Top U.S. infectious diseases expert Dr. Anthony Fauci said on Thursday that President Donald Trump's health was likely helped by an experimental therapy made by Regeneron Inc in which he received antibodies to fight the disease.

Regeneron antibodies in demand after Trump treatment, doctors seek more data

Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc <REGN.O>, and on Wednesday he promised to make it free to Americans while...

Regeneron antibodies in demand after Trump treatment, doctors seek more data

Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc, and on Wednesday he promised to make it free to Americans while touting its...

Trump credits coronavirus therapeutics, wants to make them more widely available

President Donald Trump, in a video posted on Twitter on Wednesday, credited Regeneron Pharmaceuticals Incand Eli Lilly and Co therapeutics for his recovery and said he wanted to make them more widely available.

US STOCKS-Wall Street gains with stimulus hopes, positive updates on Trump's health

* Indexes up: Dow 1.3%, S&P 1.4%, Nasdaq 1.8% (Updates to late afternoon)

Trump treated with experimental antibody cocktail for COVID-19

President Donald Trump has been treated with an experimental antibody cocktail for COVID-19 and is moving to a military hospital as a precautionary measure, White House officials said on Friday.

Trump 'fatigued but in good spirits,' his doctor says

President Donald Trump "remains fatigued but in good spirits" and is receiving treatment for the new coronavirus, the president's physician, Dr. Sean Conley, said in a statement on Friday.

Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms

Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients, enhancing its chances of becoming a treatment for the disease that has killed over a million people worldwide...

Novartis aims to expand Beovu use after safety fears hurt launch

Novartis's Beovu matched Regeneron's Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another condition caused disappointing early sales.

Regeneron's antibody drug added to UK Recovery trial of COVID treatments

The world's largest randomised trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease.

Novartis says Beovu matched rival Eylea in visual acuity in eye disease

Novartis on Monday said its eye drug Beovu matched rival Eylea from Regeneron in visual acuity at one year in patients with diabetic macular edema (DME), as the Swiss drugmaker seeks to regain momentum with the drug after early safety stumbles.

Regeneron expects to report biomarker data for COVID-19 therapy by September end

Regeneron Pharmaceuticals said on Wednesday it expects to report biomarker data for its COVID-19 antibody cocktail by the end of this month.

Sanofi says Kevzara drug fails as possible COVID-19 treatment

The rheumatoid arthritis drug Kevzara has failed as a COVID-19 treatment, French drugmaker Sanofi said on Tuesday following a similar flop of a Roche product.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up